NANJING, China

Xiaoyan Jiang

This inventor holds 2 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Bioheng Therapeutics Limited. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaoyan Jiang. Retrieved from https://idiyas.com/inventor/xiaoyan-jiang-apc9n69g

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Xiaoyan Jiang - Innovator in Cancer Treatment

Introduction

Xiaoyan Jiang is a prominent inventor based in Nanjing, China. She is currently associated with Bioheng Therapeutics Limited, where she focuses on developing innovative solutions for cancer treatment. Despite having no granted patents to her name, her contributions to the field are noteworthy.

Latest Patent Applications

Xiaoyan Jiang has been involved in several significant patent applications. One of her latest applications is for a novel chimeric antigen receptor, which includes an antigen binding region specifically targeting CD7. This receptor is designed to enhance the efficacy of engineered immune cells in treating cancers. Another application focuses on an ROR1-targeting antibody, which is part of a multispecific antibody and aims to diagnose, treat, and prevent diseases associated with ROR1 expression.

Conclusion

Xiaoyan Jiang's work at Bioheng Therapeutics Limited highlights her commitment to advancing cancer treatment through innovative research and development. Her latest patent applications reflect her dedication to improving therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…